Telomir (Nasdaq: TELO) Advances Strategic Pipeline

Through TELI Pharmaceuticals Acquisition

Good morning,

This is Michael Reece delivering you your new setup for Thu 4/30:

Telomir Pharmaceuticals (Nasdaq: TELO)

The Company has several catalysts in the pipeline and is on the verge of disrupting a $20Bn cancer epigenetics therapies space with their lead candidate Telomir-1.

Telomir-1 is the first innovative and novel small molecule targeted at lengthening the DNA’s protective telomere caps in order to affect age reversal and also treat age-related inflammatory diseases.

Telomir Pharmaceuticals (Nasdaq: TELO) just announced successful completion of its TELI Pharmaceuticals acquisition, advancing its strategic pipeline.

Erez Aminov, Chief Executive Officer of Telomir, stated “The closing of this transaction represents a defining milestone for Telomir. By securing worldwide rights to Telomir-1 (Telomir-Zn), we have established a globally unified platform as we advance toward clinical development.

Combined with our recent IND submission for Telomir-Zn, this positions the Company to progress into the clinic while maintaining the flexibility to evaluate global partnership oppor∙tunities.”

The acquisition eliminates prior geographic fragmentation of the Telomir-1 (Telomir-Zn) platform and provides Telomir with full control over development and potential commercialization across major international markets. Prior to the transaction, North American and international rights were held separately.

The closing follows Telomir’s recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Telomir-Zn for the treatment of advanced and metastatic triple-negative breast cancer.

If the IND is cleared, the Company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-Zn as an oral monotherapy in patients with advanced or metastatic triple-negative breast cancer.

Telomir Pharmaceuticals (Nasdaq: TELO) Reports
Telomir-1 Outperforms FDA-Approved Gold-Standard
Iron Chelator Deferoxamine (DFO) in Reducing
Intracellular Iron in a Human Cell Line

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity – key to its broader epigenetic mechanism of action.

TELO announced new preclinical findings showing that its lead investigational compound Telomir-1 produced a strong, dose-dependent reduction of intracellular iron in human keratinocyte (HaCaT) cells – outperforming the FDA-approved gold-standard iron chelator, Deferoxamine (DFO). These results represent an important step in Telomir’s broader program to explore how metal-ion imbalance contributes to oxidative stress, aging, and disease progression.

Erez Aminov, Chief Executive Officer of Telomir Pharmaceuticals, stated “The same metals that support growth and development early in life can, when unregulated, contribute to the very processes that drive aging and cellular decline. Our goal with Telomir-1 is to help restore that delicate balance within cells – addressing one of the fundamental factors that link metal homeostasis, oxidative stress, and biological aging. The live-cell imaging results illustrate this concept beautifully – as they say, a picture is worth a thousand words.”

Dr. Itzchak Angel, Chief Scientific Advisor, added “Iron-dependent histone demethylases sit at the intersection of redox biology and gene regulation. Telomir-1’s ability to inhibit several members of this family and to restore balance to intracellular metals provides a mechanistic framework for the methylation patterns we have previously observed. It connects metal homeostasis directly to genomic stability. The direct observation and measurements of the rapid and robust reduction of intracellular iron by Telomir-1 supports and reinforces our understanding of its mechanisms of actions”

Rodman & Renshaw Initiated Coverage
of Telomir Pharmaceuticals (Nasdaq: TELO)
with a B∙uy rating and $8.00 Price Target

>>> (Representing 450% in Upside Potential) <<<

Initiating with B∙uy Rating and $8.00 PT

Wall Street Analyst Michael King at Rodman & Renshaw initiated coverage of Telomir

Pharmaceuticals (Nasdaq: TELO) with a B∙uy rating and $8 price target, highlighting their drug candidate’s application across multiple high-value indications as a key factor in its bullish outlook.

The research firm cited Telomir-1’s potential as a first-in-class epigenetic therapeutic that targets fundamental mechanisms of cellular aging. Telomir Pharmaceuticals announced preclinical results for its investigational compound Telomir-1 in triple-negative breast cancer (TNBC) models. The study showed that Telomir-1 was effective both as a standalone treatment and in combination with paclitaxel, a chemotherapy agent, across various laboratory TNBC models. Additionally, Telomir Pharmaceuticals reported that Telomir-1 reduced prostate-specific antigen (PSA) levels in androgen-responsive human prostate cancer cells, highlighting its potential in prostate cancer treatment.

In another development, the company revealed new laboratory findings demonstrating that Telomir-1 effectively kills aggressive human leukemia cells, expanding its potential applications into blood cancers.

Investing.com Technical Opinion
Update Puts TELO on Watch

Recent technical indicators are signaling a favorable setup based on Investing.com analysis.

Key Catalysts Putting TELO on Radar

• Telomir Reaches IND Milestone for Telomir-1 in Triple-Negative Breast Cancer FDA IND Submission.
• Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn).
• Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer.
• Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells.
• Wall Street Analyst Michael King at Rodman & Renshaw initiated coverage of Telomir Pharmaceuticals with a B∙uy rating and $8 price target, highlighting their drug candidate’s application across multiple high-value indications as a key factor in its bullish outlook.

I am urging all of our members to add TELO to the top of your watch list.

To your success,

Michael Reece

Editor, Financial Driven Research

© 2026 FinancialDrivenResearch.com. All rights reserved. You are receiving this e-mail as part of your subscription to FinancialDrivenResearch.com. Nothing in this e-mail should be considered personalized financial advice. We are neither a registered investment adviser nor a broker/dealer. Readers are advised that this electronic publication is issued solely for information purposes only and should not be construed as an offer to sell or the solicitation of an offer to buy any security. FDR is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. This communication is sponsored. Pursuant to an agreement between FDR and STM LLC. FDR has been compensated seven thousand five hundred USD to publicly disseminate information about TELO via digital communications. We maintain zero positions in all profiles and do not trade in any securities we feature. We do not, under any circumstance, accept shares as compensation for sponsored profiles.

© 2026 FDR. All rights reserved, 1014 W 36th St, Baltimore, MD 21211, United States of America

You may unsubscribe or change your contact details at any time.